A Chinese biopharma venture founded in 2017 just snatched up a Canadian biotech developing an mRNA COVID-19 vaccine to bring more effective vaccine technology to China. Of late, China has pivoted to combat COVID-19 not only with the so-called “zero-tolerance” policy—an ongoing series of actions to keep SARS-CoV-2 infections out of the country—but also mass vaccination. Complicating this latter approach are what increasingly appear to be subpar vaccine products such as those produced by Sinovac, Sinopharm, and CanSino Biologics. China seeks advanced technology from the west to improve the effectiveness and durability of vaccination targeting COVID-19. Hence the move by Everest Medicines Ltd. to ink a licensing deal with Canada’s Providence Therapeutics Holdings Inc.
TrialSite InvestorWatch provides an overview.
Why did Everest Medicines Ltd. license this mRNA vaccine developed in Canada?
To capitalize on existing intellectual property (IP) and gain access to superior western vaccine technology targeting COVID-19.
What is the underlying technology?
Providence Therapeutics Holdings uses mRNA technology based on advantages such as the ability to design and produce ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).